Rajeev Raghuvanshi Receives One-Year Extension as India's Top Pharmaceutical Regulator

India's Top Drug Regulator Gets One-Year Extension

The Centre has approved a one-year extension for Rajeev Singh Raghuvanshi as the Drugs Controller General of India (DCGI), effective March 1. This extension allows Raghuvanshi to continue in the role on a contract basis, despite the government keeping regular recruitment rules for the post in abeyance.

Raghuvanshi's Tenure and Background

Raghuvanshi's tenure began in February 2023, when he transitioned from his role as Secretary-cum-Scientific Director of the Indian Pharmacopoeia Commission. A veteran of the pharmaceutical industry, Raghuvanshi has held previous leadership roles at Dr. Reddy's Laboratories and Ranbaxy. His appointment was initially seen as an effort to bring private-sector technical expertise to a role traditionally held by career bureaucrats or internal promotees.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Regulatory Reforms and Initiatives

Raghuvanshi's performance has been characterized by an aggressive "clean-up" of the domestic manufacturing landscape. Following global reports of contaminated cough syrups, he oversaw a nationwide crackdown that included the inspection of approximately 1,100 manufacturing units and the issuance of over 850 corrective action notices. His administration pushed through the revised Schedule M norms, which mandated that Indian factories meet Good Manufacturing Practices (GMP) closer to those required by the USFDA. To increase transparency, the CDSCO also launched a digital dashboard to track drugs that fail "Not of Standard Quality" (NSQ) tests.

Challenges and Criticism

Despite these initiatives, Raghuvanshi's leadership has faced persistent criticism and legal hurdles. The government's decision to bypass standard recruitment procedures to retain him has been challenged in the Madurai bench of the Madras High Court, with critics questioning the transparency of the appointment process. Additionally, his tenure has been marked by allegations from some industry quarters regarding "perception management" and the speed of specific drug approvals, as well as public debate over the clarity of data released regarding the prevalence of spurious versus sub-standard drugs in the Indian market.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline